explore -WSS

explore

author：leisure time 2025-10-02 22:41:16 - browse：9691

An experimental drug from Insmed Incorporated successfully reduced lung problems among patients with an airway disease in a closely watched Phase 3 trial, sending the company’s share price soaring early Tuesday.

The drug, brensocatib, reduced so-called pulmonary exacerbations by roughly 20% versus placebo in patients with bronchiectasis, hitting the trial’s primary endpoint. The trial, called the ASPEN study, tested two dosages of the drug, and the company said both significantly cut rates of pulmonary exacerbations.

Insmed shares more than doubled in pre-market trading. Analysts have forecasted that brensocatib could lead to billions of dollars in annual sales if approved.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Statins may not be needed by millions of people, study suggests

hotspot

WSS

Pharma companies must ensure equitable access to obesity drugs

Deposition: Sackler embraced plan to conceal OxyContin’s strength

'Essentially witchcraft:' A former naturopath takes on the field

FDA does about

In search for therapies for solid tumors, companies turn to claudin

Obesity now affects over 1 billion people worldwide, study finds

focus

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Scientists unlock the key to scar

As demand for Covid shots wanes, Moderna seeks its next success

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Dobbs anniversary: the lost opportunity of abortion as health care

How to address the problem of discarded donor organs

Apple is now the first public company to be valued at $3 trillion

FogPharma raises $145 million in rare Series E round

The cancer drug shortage isn’t new — and neither are the solutions

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

entertainment

Pfizer highlights cancer drugs it thinks could reignite investor interest

Curing rare childhood diseases will falter unless Congress steps up

Teladoc has a new CEO, but challenges remain the same

Clinical trials giant ICON acquires HumanFirst

Change Healthcare cyberattack outage could last weeks

In search for therapies for solid tumors, companies turn to claudin

hotspot

explore

entertainment

entertainment